Study analysis · European journal of preventive cardiology · 2025
Remnant cholesterol looked like a cardiovascular superstar—until researchers adjusted for LDL cholesterol.
In 43 cholesterol-lowering trials, lowering remnant cholesterol was linked to fewer heart events, but much of that link overlapped with LDL cholesterol lowering, and the actual number of events prevented per person wasn't reported.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine you combine the results of many experiments. This study did that and found that when people's remnant cholesterol goes down, their chance of heart problems also goes down. But it doesn't prove that lowering remnant cholesterol is the direct cause of fewer heart problems—just that they happen together.
What’s the bottom line?
Researchers combined 43 trials of statins, ezetimibe, and PCSK9 inhibitors to see whether lowering remnant cholesterol is linked to fewer heart attacks and related events.
How strong is this study?
This study looked at a huge number of people, which is good. But we only have a short summary, not all the details about how each experiment was done. So we can't be sure how trustworthy the exact numbers are.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=327264)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design cannot establish causation — the findings describe an association, not a cause. Meta-analysis of trials, but randomization of included trials is not explicitly stated in the abstract; even if randomized, meta-regression of trial-level data cannot establish causation. Observational associations are subject to confounding and ecological bias.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information was provided in the abstract, so the potential for bias cannot be assessed.
The abstract does not include a conflict of interest, funding, or author affiliation section. This analysis is limited to the provided text; the full article may contain relevant disclosures.
Key takeaways
- 01
Per 1 mmol/L (39 mg/dL) reduction: LDL cholesterol lowering had a relative risk ratio of 0.84 fixed/0.82 random for major cardiovascular events; remnant cholesterol lowering had a relative risk ratio of 0.36 fixed/0.27 random.
- 02
After adjusting for LDL, remnant cholesterol's relative risk ratio was 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05).
- 03
The study did not report absolute risk reduction.
- 04
Overall, 42,016 major cardiovascular events occurred among 327,264 participants, which is about 13% over the trial follow-up periods, but follow-up duration is not specified.
- 05
Because absolute risk reduction was not reported, we cannot say how many fewer events per 1,000 people came from remnant cholesterol lowering.
Practical takeaways
Do not use this abstract to change clinical practice or add remnant-cholesterol-specific treatments; the absolute risk reduction was not reported and corrections/errata exist.
Full text was unavailable; methodology cannot be verified; the study is a meta-analysis of trial-level associations, not individual-level causal proof.
low confidenceFor now, keep focusing on proven LDL-lowering strategies if they are clinically indicated; this study does not show that remnant cholesterol is an independent target.
The abstract only reports association and does not specify clinical implications; no absolute benefit data.
low confidenceWhy this study matters
The eye-popping unadjusted number
Per 1 mmol/L (39 mg/dL) reduction, remnant cholesterol had a relative risk ratio for MACE of 0.36 fixed (95% CI 0.33–0.40) and 0.27 random (0.20–0.36). LDL cholesterol's relative risk ratio was 0.84 fixed (0.82–0.85) and 0.82 random (0.78–0.85). These are relative risk ratios, not absolute risk reductions.
It makes remnant cholesterol seem like a far more powerful target than LDL, which would be huge if true.
Adjustment shrinks the signal
After adjusting for LDL cholesterol reduction, remnant cholesterol's association weakened: per 1 mmol/L, random-effects relative risk ratio 0.92 (95% CI 0.45–1.187); per 1 SD, 0.99 (95% CI 0.94–1.05). Much of the apparent remnant benefit overlapped with LDL lowering.
It shows why a striking signal in trials can vanish once you account for the main cholesterol driver.
They move together
For every 1 mmol/L (39 mg/dL) LDL reduction, remnant cholesterol fell 0.19 mmol/L; for every 20% LDL reduction, remnant cholesterol fell 11%. This correlation makes it hard to separate their independent effects.
It explains the statistical headache: two variables changing together are tough to untangle.
Huge data, missing absolute risk
The meta-analysis included 43 trials, 327,264 participants, and 42,016 MACE (~12.8% over follow-up, duration not specified). But absolute risk reduction was not reported, so we don't know how many events were prevented per 1,000 people.
Big relative numbers can sound impressive while leaving the real-world benefit unclear.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers combined 43 trials of statins, ezetimibe, and PCSK9 inhibitors to see whether lowering remnant cholesterol is linked to fewer heart attacks and related events.
Research results
Per 1 mmol/L (39 mg/dL) reduction: LDL cholesterol lowering had a relative risk ratio of 0.84 fixed/0.82 random for major cardiovascular events; remnant cholesterol lowering had a relative risk ratio of 0.36 fixed/0.27 random. After adjusting for LDL, remnant cholesterol's relative risk ratio was 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05).
What this means - more context
The study did not report absolute risk reduction. Overall, 42,016 major cardiovascular events occurred among 327,264 participants, which is about 13% over the trial follow-up periods, but follow-up duration is not specified. Because absolute risk reduction was not reported, we cannot say how many fewer events per 1,000 people came from remnant cholesterol lowering.
Tested whether remnant cholesterol reduction is associated with part of the cardiovascular risk reduction seen in statin, ezetimibe, and PCSK9 inhibitor trials.
Meta-regression of 43 trials (327,264 participants; 42,016 major adverse cardiovascular events). Remnant cholesterol fell 0.19 mmol/L per 1 mmol/L LDL cholesterol reduction and 11% per 20% LDL reduction. Relative risk ratios for MACE per 1 mmol/L reduction were 0.84 fixed/0.82 random for LDL and 0.36 fixed/0.27 random for remnant cholesterol. After adjustment for LDL cholesterol, the remnant cholesterol association attenuated to 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05). Absolute risk reduction was not reported. Note: PubMed indicates corrections/errata; readers should check correction notices for updated information.
Methods Used
Included statin, ezetimibe, and PCSK9 inhibitor trials with ≥1000 participants and lipid data. Baseline and follow-up LDL and remnant cholesterol levels were extracted; reductions were intervention-reference differences at year one. Meta-regressions calculated risk ratios for MACE per 1 mmol/L (39 mg/dL) and 1 SD reductions. Full methodology not available in abstract.
Main Finding
Remnant cholesterol lowering is associated with part of the cardiovascular risk reduction in these trials. Per 1 mmol/L reduction, the relative risk ratio for MACE was 0.36 fixed (0.33–0.40) and 0.27 random (0.20–0.36) for remnant cholesterol, versus 0.84 fixed (0.82–0.85) and 0.82 random (0.78–0.85) for LDL cholesterol. After adjustment for LDL cholesterol reduction, the remnant cholesterol relative risk ratio was 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05), indicating much overlap with LDL cholesterol lowering. Absolute risk reduction was not reported; overall 42,016 MACE occurred among 327,264 participants (~12.8% over trial follow-up, duration not specified).
Confidence Level
Limited - based on abstract only, full methodology not available; corrections/errata exist and should be checked.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Corrections/errata exist; readers should check correction notices for updated information
- •Absolute risk reduction was not reported, limiting interpretation of clinical impact
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
Do not use this abstract to change clinical practice or add remnant-cholesterol-specific treatments; the absolute risk reduction was not reported and corrections/errata exist.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
Imagine you combine the results of many experiments. This study did that and found that when people's remnant cholesterol goes down, their chance of heart problems also goes down. But it doesn't prove that lowering remnant cholesterol is the direct cause of fewer heart problems—just that they happen together.
Strengths
- Large sample size (327,264 participants)
- Meta-analysis of 43 trials
- Meta-regression allows adjustment for LDL and remnant cholesterol
Weaknesses
- Full methodology not available - based on abstract only
- Randomization and blinding of included trials not explicitly stated in abstract
- Meta-regression is observational and cannot establish causation
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers combined 43 trials of statins, ezetimibe, and PCSK9 inhibitors to see whether lowering remnant cholesterol is linked to fewer heart attacks and related events.
Research results
Per 1 mmol/L (39 mg/dL) reduction: LDL cholesterol lowering had a relative risk ratio of 0.84 fixed/0.82 random for major cardiovascular events; remnant cholesterol lowering had a relative risk ratio of 0.36 fixed/0.27 random. After adjusting for LDL, remnant cholesterol's relative risk ratio was 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05).
What this means - more context
The study did not report absolute risk reduction. Overall, 42,016 major cardiovascular events occurred among 327,264 participants, which is about 13% over the trial follow-up periods, but follow-up duration is not specified. Because absolute risk reduction was not reported, we cannot say how many fewer events per 1,000 people came from remnant cholesterol lowering.
Tested whether remnant cholesterol reduction is associated with part of the cardiovascular risk reduction seen in statin, ezetimibe, and PCSK9 inhibitor trials.
Meta-regression of 43 trials (327,264 participants; 42,016 major adverse cardiovascular events). Remnant cholesterol fell 0.19 mmol/L per 1 mmol/L LDL cholesterol reduction and 11% per 20% LDL reduction. Relative risk ratios for MACE per 1 mmol/L reduction were 0.84 fixed/0.82 random for LDL and 0.36 fixed/0.27 random for remnant cholesterol. After adjustment for LDL cholesterol, the remnant cholesterol association attenuated to 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05). Absolute risk reduction was not reported. Note: PubMed indicates corrections/errata; readers should check correction notices for updated information.
Methods Used
Included statin, ezetimibe, and PCSK9 inhibitor trials with ≥1000 participants and lipid data. Baseline and follow-up LDL and remnant cholesterol levels were extracted; reductions were intervention-reference differences at year one. Meta-regressions calculated risk ratios for MACE per 1 mmol/L (39 mg/dL) and 1 SD reductions. Full methodology not available in abstract.
Main Finding
Remnant cholesterol lowering is associated with part of the cardiovascular risk reduction in these trials. Per 1 mmol/L reduction, the relative risk ratio for MACE was 0.36 fixed (0.33–0.40) and 0.27 random (0.20–0.36) for remnant cholesterol, versus 0.84 fixed (0.82–0.85) and 0.82 random (0.78–0.85) for LDL cholesterol. After adjustment for LDL cholesterol reduction, the remnant cholesterol relative risk ratio was 0.92 random (95% CI 0.45–1.187) per 1 mmol/L and 0.99 per 1 SD (95% CI 0.94–1.05), indicating much overlap with LDL cholesterol lowering. Absolute risk reduction was not reported; overall 42,016 MACE occurred among 327,264 participants (~12.8% over trial follow-up, duration not specified).
Confidence Level
Limited - based on abstract only, full methodology not available; corrections/errata exist and should be checked.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Corrections/errata exist; readers should check correction notices for updated information
- •Absolute risk reduction was not reported, limiting interpretation of clinical impact
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
Do not use this abstract to change clinical practice or add remnant-cholesterol-specific treatments; the absolute risk reduction was not reported and corrections/errata exist.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Moderate probability
on the GRADE evidence scale
Imagine you combine the results of many experiments. This study did that and found that when people's remnant cholesterol goes down, their chance of heart problems also goes down. But it doesn't prove that lowering remnant cholesterol is the direct cause of fewer heart problems—just that they happen together.
Strengths
- Large sample size (327,264 participants)
- Meta-analysis of 43 trials
- Meta-regression allows adjustment for LDL and remnant cholesterol
Weaknesses
- Full methodology not available - based on abstract only
- Randomization and blinding of included trials not explicitly stated in abstract
- Meta-regression is observational and cannot establish causation
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study looked at a huge number of people, which is good. But we only have a short summary, not all the details about how each experiment was done. So we can't be sure how trustworthy the exact numbers are.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=327264)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 549 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design cannot establish causation — the findings describe an association, not a cause. Meta-analysis of trials, but randomization of included trials is not explicitly stated in the abstract; even if randomized, meta-regression of trial-level data cannot establish causation. Observational associations are subject to confounding and ecological bias.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information was provided in the abstract, so the potential for bias cannot be assessed.
The abstract does not include a conflict of interest, funding, or author affiliation section. This analysis is limited to the provided text; the full article may contain relevant disclosures.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
2 researchersIf this is your work, this is how we attribute it on Fit Body Science. Ask Tybjærg Nordestgaard is listed as the lead author.